ClinicalTrials.gg
TerminatedNCT02351037Updated Aug 14, 2018Results posted

Study of Ibrutinib in Subjects With Acute Myeloid Leukemia

A Phase 2 interventional study of Ibrutinib and Ibrutinib + LD-AraC in Acute Myeloid Leukemia (AML), sponsored by Pharmacyclics LLC.. Terminated at 9 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-08-14.

Sponsored by Pharmacyclics LLC. (part of AbbVie) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study data do not support development in AML.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 214 studies testing azacitidine in Leukemia, Myeloid, Acute — 72 open to participants now, 91 under way, 11 of them phase 3. Azacitidine · Leukemia, Myeloid, Acute.

Enrollment
134th of 211
36 · median 50
Started
2015
with 7 others
Phase 2
105 of 214
40 open now
Registered
65th of 214
by date

Among the 214 studies testing azacitidine in Leukemia, Myeloid, Acute, this one is the 134th largest by enrollment of the 211 interventional ones that give a count, is one of 8 that started in 2015, is one of 105 in phase 2, and was the 65th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 817 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

72 of the 214 studies testing azacitidine in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

67 more — sign in →

By country, each count listing its studies:

All 72 open studies →

About azacitidine

Azacitidine: first FDA approval 2004 (VIDAZA), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies testing azacitidine in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy, safety and tolerability of ibrutinib alone or in combination with either cytarabine or azacitidine in the treatment of subjects with Acute Myeloid Leukemia (AML) who have failed standard treatment, or subjects without prior therapy who refuse standard chemotherapy.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute Myeloid Leukemia
  • AML
  • Ibrutinib
  • Cytarabine
  • LD-AraC
  • Azacitidine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female ≥ 18 years of age.
  • (ECOG) performance status of 0-2
  • Subjects with documented AML that has failed standard treatment, or subjects without prior therapy who refuse standard treatment options
  • Bone marrow aspirate/ results showing >5% blasts
  • WBC count \<25,000 cells/mm3 (25 x 109/L)
  • count >10,000 cells/mm3 (10 x 109/L)
  • Adequate hepatic and renal function defined as:

    • For Cohorts 1 and 2: serum (AST) or alanine transaminase (ALT) ≤3.0 x (ULN); for Cohort 3: ALT ≤2.5 or AST ≤2.5 ULN.
    • Serum creatinine ≤2 mg/dL or Estimated ≥30 mL/min (Cockcroft-Gault).
    • ≤1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin).
  • \<1.5 x ULN and PTT (aPTT) \<1.5 x ULN (When treated with warfarin or other vitamin K antagonists, then INR ≤3.0).
  • Female subjects who are of non- (Female subjects of reproductive potential must have a negative serum pregnancy test upon study entry).
  • Male and female subjects of reproductive potential agree to use highly effective methods of (e.g., condoms, implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence, or sterilized partner) during the period of therapy and for 90 days after the last dose of study drug.

Exclusion criteria

Exclusion Criteria:

  • Acute promyelocytic leukemia (French-American-British Class M3 AML).
  • Known active central nervous system (CNS) leukemia.
  • Known active systemic infection (Grade ≥2).
  • Active bleeding disorders or clinical signs of bleeding (Grade ≥2).
  • Prior bone marrow transplant that requires therapy or presents with graft vs host disease ().
  • History of other , except:

    • Malignancy treated with curative intent and with no known active disease present for ≥3 years before the first dose of study drug and with low risk of recurrence by treating physician.
    • Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease.
    • Adequately treated carcinoma in situ without evidence of disease.
  • Prior treatment with a BTK inhibitor.
  • For Cohort 3 subjects, prior treatment with hypomethylating agents (eg, azacitidine, decitabine)
  • Anticancer therapy including chemotherapy, immunotherapy, radiotherapy, hormonal or any therapy within 14 days or 5 half-lives (whichever is shorter) prior to first dose of study drug.
  • Subject has received a monoclonal antibody for anticancer intent within 8 weeks prior to the first dose of study drug.
  • Vaccinated with live, attenuated vaccines within 4 weeks of first dose of study drug.
  • Recent infection requiring intravenous (IV) systemic treatment that was completed ≤14 days before the first dose of study drug.
  • Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Common Terminology Criteria for Adverse Event (, version 4.03), Grade 0 or 1, unless otherwise defined in the inclusion/exclusion criteria with the exception of alopecia.
  • Known bleeding disorders (e.g., von Willebrand's disease) or hemophilia.
  • History of stroke or intracranial hemorrhage within 6 months prior to enrollment.
  • Known history of (HIV) or active with virus (HCV) or virus (HBV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.
  • Major surgery within 4 weeks of first dose of study drug.
  • Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk.
  • Currently active, cardiovascular disease, such as uncontrolled arrhythmia or Class 3 or 4 congestive heart failure as defined by the Functional Classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to randomization.
  • Unable to swallow capsules or malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction.
  • Concomitant use of warfarin or other Vitamin K antagonists.
  • Requires treatment or prophylaxis with a strong cytochrome P450 (CYP) 3A inhibitor
  • Currently active, clinically significant hepatic impairment (≥ moderate hepatic impairment according to the classification).
  • Lactating or pregnant.
  • Unwilling or unable to participate in all required study evaluations and procedures.
  • Unable to understand the purpose and risks of the study and to provide a signed and dated form (ICF) and authorization to use protected health information (in accordance with national and local subject privacy regulations).
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Ibrutinib Monotherapy Cohort

    Up to 33 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis.

    Drug: Ibrutinib

  • Experimental
    Ibrutinib + LD-AraC Combination Cohort

    Up to 25-28 additional response evaluable subjects (for a total of 34 subjects) will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.

    Drug: Ibrutinib + LD-AraC

  • Experimental
    Ibrutinib+Azacitidine Combination Cohort

    Up to 34 response evaluable subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75mg/m2 IV once daily Days 1-7 of a 28-day cycle (with an option to increase to 100mg/m2 after 2 cycles).

    Drug: Ibrutinib+Azacitidine

Interventions

  • Subjects will receive ibrutinib 560 mg once daily on a continuing basis.

    Also known as: Cohort 1

  • DrugIbrutinib + LD-AraC

    Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.

    Also known as: Cohort 2

  • DrugIbrutinib+Azacitidine

    Drug pages: Ibrutinib · Azacitidine

    Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).

    Also known as: Cohort 3

06

What researchers measure

Primary outcomes

  1. Efficacy of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Using the Overall Remission Rate (Defined as Proportion of Subjects Achieving a CR or CRi) According to the LeukemiaNet Guidelines

    Dohner's 2000 Criteria for AML: Complete Response (CR), Bone marrow blasts \< 5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \> 1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100 000/µL); independence of red cell transfusions; CR with Incomplete Recovery (CRi), All CR criteria except for residual neutropenia (\< 1.0 x 109/L \[1000/µL\]) or thrombocytopenia (\<100 x 109/L \[100 000/µL\]) ; Morphologic leukemia-free state, Bone marrow blasts \< 5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required; Partial Remission (PR), All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%; Relapse, Bone marrow blasts \> 5%; or reappearance of blasts in the blood; or development of extramedullary disease.

    Time frame: When the last subject enrolled completes approximately 12 months of treatment.

  2. Safety and Tolerability of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine

    Number of Participants with Adverse Events and number of patients with lab abnormalities.The safety profile of ibrutinib was evaluated based on the incidence of adverse events (AEs) as well as clinically significant laboratory abnormalities and vital signs, and other malignancies. The safety evaluations performed in this study were standard and/or were required based on the safety data available from other clinical and preclinical settings.

    Time frame: Up to 30 days following the last dose of study drug.

Secondary outcomes

  1. Relapse-free Survival (RFS), Event-free Survival (EFS) and Overall Survival (OS)

    To evaluate clinical efficacy by assessing relapse-free survival (RFS), event-free survival (EFS) and overall survival (OS).

    Time frame: When the last subject enrolled completes approximately 12 months of treatment

  2. Clinical Benefit Rate - as Defined as the Proportion of Subjects Who Achieve CR, CRi, Morphologic Leukemia-free State, or Partial Remission (PR)

    To evaluate clinical benefit defined as CR, CRi, morphologic leukemia-free state, and partial remission (PR).

    Time frame: When the last subject enrolled completes approximately 12 months of treatment

07

Results

Posted Aug 14, 2018

Participant flow

Participant flow — Overall Study
MilestoneIbrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination Cohort
Started7218
Completed7218
Not completed000

Outcome measures

PrimaryEfficacy of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Using the Overall Remission Rate (Defined as Proportion of Subjects Achieving a CR or CRi) According to the LeukemiaNet Guidelines

Dohner's 2000 Criteria for AML: Complete Response (CR), Bone marrow blasts \< 5%; absence of blasts with Auer rods; absence of extramedullary disease; absolute neutrophil count \> 1.0 x 109/L (1000/µL); platelet count \>100 x 109/L (100 000/µL); independence of red cell transfusions; CR with Incomplete Recovery (CRi), All CR criteria except for residual neutropenia (\< 1.0 x 109/L \[1000/µL\]) or thrombocytopenia (\<100 x 109/L \[100 000/µL\]) ; Morphologic leukemia-free state, Bone marrow blasts \< 5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required; Partial Remission (PR), All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%; Relapse, Bone marrow blasts \> 5%; or reappearance of blasts in the blood; or development of extramedullary disease.

Time frame:
When the last subject enrolled completes approximately 12 months of treatment.
Reported as:
Count of participants · Participants
Efficacy of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Using the Overall Remission Rate (Defined as Proportion of Subjects Achieving a CR or CRi) According to the LeukemiaNet Guidelines
ParticipantsIbrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination Cohort
Efficacy of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine Using the Overall Remission Rate (Defined as Proportion of Subjects Achieving a CR or CRi) According to the LeukemiaNet Guidelines010
PrimarySafety and Tolerability of Ibrutinib Monotherapy or in Combination With Either LD-AraC or Azacitidine

Number of Participants with Adverse Events and number of patients with lab abnormalities.The safety profile of ibrutinib was evaluated based on the incidence of adverse events (AEs) as well as clinically significant laboratory abnormalities and vital signs, and other malignancies. The safety evaluations performed in this study were standard and/or were required based on the safety data available from other clinical and preclinical settings.

Time frame:
Up to 30 days following the last dose of study drug.

Results for this outcome have not been posted.

SecondaryRelapse-free Survival (RFS), Event-free Survival (EFS) and Overall Survival (OS)

To evaluate clinical efficacy by assessing relapse-free survival (RFS), event-free survival (EFS) and overall survival (OS).

Time frame:
When the last subject enrolled completes approximately 12 months of treatment

Results for this outcome have not been posted.

SecondaryClinical Benefit Rate - as Defined as the Proportion of Subjects Who Achieve CR, CRi, Morphologic Leukemia-free State, or Partial Remission (PR)

To evaluate clinical benefit defined as CR, CRi, morphologic leukemia-free state, and partial remission (PR).

Time frame:
When the last subject enrolled completes approximately 12 months of treatment

Results for this outcome have not been posted.

Adverse events

Collected over 2 years, 4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ibrutinib Monotherapy Cohort7/7 (100%)4/7 (57.1%)7/7 (100%)
Ibrutinib + LD-AraC Combination Cohort21/21 (100%)21/21 (100%)21/21 (100%)
Ibrutinib+Azacitidine Combination Cohort8/8 (100%)8/8 (100%)8/8 (100%)
Most frequent serious events
Showing 10 of 46
Most frequent serious events
EventIbrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination Cohort
Febrile neutropeniaBlood and lymphatic system disorders1/76/214/8
Acute myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/79/210/8
PneumoniaInfections and infestations0/78/211/8
BacteraemiaInfections and infestations1/71/210/8
Pneumonia fungalInfections and infestations0/73/210/8
VulvitisInfections and infestations1/70/210/8
Failure to thriveMetabolism and nutrition disorders1/70/210/8
Respiratory failureRespiratory, thoracic and mediastinal disorders0/73/211/8
Lung infectionInfections and infestations1/70/210/8
StomatitisGastrointestinal disorders0/70/211/8
Most frequent other events
Showing 10 of 134
Most frequent other events
EventIbrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination Cohort
ThrombocytopeniaBlood and lymphatic system disorders0/72/215/8
CoughRespiratory, thoracic and mediastinal disorders1/74/215/8
FatigueGeneral disorders2/712/212/8
Decreased appetiteMetabolism and nutrition disorders1/711/211/8
AnaemiaBlood and lymphatic system disorders2/75/214/8
DiarrhoeaGastrointestinal disorders3/710/213/8
Oedema peripheralGeneral disorders3/710/213/8
NauseaGastrointestinal disorders3/78/213/8
HypoalbuminaemiaMetabolism and nutrition disorders3/74/211/8
DyspnoeaRespiratory, thoracic and mediastinal disorders1/78/212/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Ibrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination CohortTotal
<=18 years0000
Between 18 and 65 years45615
>=65 years316221
Age, Continuous
Age, Continuous(years)Ibrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination CohortTotal
Mean67 ± 11.770 ± 9.158 ± 12.467 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)Ibrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination CohortTotal
Female37616
Male414220
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ibrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination CohortTotal
Hispanic or Latino1225
Not Hispanic or Latino619631
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ibrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination CohortTotal
American Indian or Alaska Native0000
Asian0101
Native Hawaiian or Other Pacific Islander0000
Black or African American1102
White619833
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(participants)Ibrutinib Monotherapy CohortIbrutinib + LD-AraC Combination CohortIbrutinib+Azacitidine Combination CohortTotal
United States721836
08

Study locations

9 sites
  • City of Hope
    Duarte, California 91010, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • The University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland 21231, United States
  • Montefiore Einstein Center for Cancer Research
    Bronx, New York 10461, United States
  • Roswell Park Cancer Institute
    Buffalo, New York 14263, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Fred Hutchinson Cancer Research Center
    Seattle, Washington 98109, United States
09

References and documents

Publications

  • Wilken R, Li CS, Sharon VR, Kim K, Patel FB, Patel F, Maverakis E. Topical clobetasol for the treatment of toxic epidermal necrolysis: study protocol for a randomized controlled trial. Trials. 2015 Aug 22;16:374. doi: 10.1186/s13063-015-0879-7. PubMed 26297574 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2015 to primary completion in Apr 2017, 26 months.

Results were first posted in Aug 2018, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 16, 2015
First posted
Jan 30, 2015
StartActual
Feb 2015
Primary completionActual
Apr 2017
CompletionActual
Apr 2017
Results first posted
Aug 14, 2018
Last update
Aug 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02351037
Lead sponsor
Pharmacyclics LLC.
Responsible party
Sponsor
First posted
Jan 30, 2015
Start date
Feb 2015
Primary completion
Apr 2017
Completion
Apr 2017
Results posted
Aug 14, 2018
Last update
Aug 14, 2018

Study contacts

Jorge Cortes, MD
principal investigator · M.D. Anderson Cancer Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibrutinib · Azacitidine

Start the discussion